Importantly, inhibition of FGFR signaling via dominant-negative FGFR1 [18], FGF2 neutralizing antibodies [19], FGFR TKI [11] or anti-sense RNA [11], [19] approaches blocked proliferation of tumor growth in NSCLC. The gene discussed is FGF2; the disease is non-small cell lung carcinoma.